Revista Brasileira De Reumatologia最新文献

{"title":"Influência do tratamento periodontal na artrite reumatoide: revisão sistemática e metanálise","authors":"Débora Cerqueira Calderaro ,&nbsp;Jôice Dias Corrêa ,&nbsp;Gilda Aparecida Ferreira ,&nbsp;Izabela Guimarães Barbosa ,&nbsp;Carolina Castro Martins ,&nbsp;Tarcília Aparecida Silva ,&nbsp;Antônio Lúcio Teixeira","doi":"10.1016/j.rbr.2016.10.002","DOIUrl":"10.1016/j.rbr.2016.10.002","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the influence of periodontal treatment on rheumatoid arthritis activity.</p></div><div><h3>Methods</h3><p>MEDLINE/PUBMED, The Cochrane Library, Clinical Trials, SciELO and LILACS were searched for studies published until December 2014. Included articles were: prospective studies; including patients older than 18 years, diagnosed with periodontitis and rheumatoid arthritis submitted to non‐surgical periodontal treatment; with a control group receiving no periodontal treatment; with outcomes including at least one marker of rheumatoid arthritis activity. Methodological quality of the studies was assessed using PEDro scale. Quantitative data were pooled in statistical meta‐analysis using Review Manager 5.</p></div><div><h3>Results</h3><p>Four articles were included. Non‐surgical periodontal treatment was associated with a significant reduction of DAS28 (OR: −1.18; 95% CI: −1.43, −0.93; p &lt;0.00001). Erythrocyte sedimentation rate, C‐reactive protein, patient's assessment of rheumatoid activity using visual analogical scale, tender and swollen joint counts showed a trend towards reduction (not statistically significant).</p></div><div><h3>Conclusions</h3><p>The reduction of DAS 28 in patients with rheumatoid arthritis after periodontal treatment suggests that the improvement of periodontal condition is beneficial to these patients. Further randomized controlled clinical trials are necessary to confirm this finding.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47736235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tratamento da tuberculose latente em pacientes com doenças reumáticas juvenis: uma revisão sistemática","authors":"José Cleosmaque Leite Júnior ,&nbsp;Regina Terse Trindade Ramos ,&nbsp;Teresa Cristina Martins Vicente Robazzi","doi":"10.1016/j.rbr.2016.11.005","DOIUrl":"https://doi.org/10.1016/j.rbr.2016.11.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Children and adolescents with rheumatic diseases receiving TNF blockers are at risk for the activation of latent <em>Mycobacterium tuberculosis</em> infection (LTBI). Although LTBI treatment is indicated in this group, there are different therapeutic regimens in the literature, without a definite consensus.</p></div><div><h3>Objectives</h3><p>To review in the literature therapeutic schemes used and indicated for the treatment of LTBI in these patients.</p></div><div><h3>Methods</h3><p>Systematic review of the literature, using health databases, selecting studies that addressed the treatment of LTBI in patients with juvenile rheumatic diseases using TNF blockers, from 1990 to 2015. All study designs were considered.</p></div><div><h3>Results</h3><p>A total of 162 studies were identified through the electronic databases and one was found through a manual search by the author, totaling 163 articles. We excluded studies that did not meet the mentioned inclusion criteria, and included a retrospective cohort study and two prospective cohort studies. The three studies addressed treatment with isoniazid (INH) for 9 months and one of them also addressed INH treatment associated with rifampicin for 3 months.</p></div><div><h3>Conclusions</h3><p>Only one case of LTBI activation was observed; there was good treatment adherence and absence of complications during follow‐up. More studies are necessary to evaluate the response to the other available therapeutic regimens, with better tolerability assessment and a larger sample. However, the results showed that INH therapy for 9 months and INH therapy plus rifampicin for 3 months had a low rate of LTBI activation and complications.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.11.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137005378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associação entre doença desmielinizante e doença reumática autoimune em uma população pediátrica","authors":"Ana Luiza M. Amorim ,&nbsp;Nadia C. Cabral ,&nbsp;Fabiane M. Osaku ,&nbsp;Claudio A. Len ,&nbsp;Enedina M.L. Oliveira ,&nbsp;Maria Teresa Terreri","doi":"10.1016/j.rbr.2016.08.004","DOIUrl":"10.1016/j.rbr.2016.08.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Multiple sclerosis (MS) and neuromyelitis optica (NMO) are demyelinating diseases of the central nervous system. Autoimmunity in patients with demyelinating disease and in their families has been broadly investigated and discussed. Recent studies show a higher incidence of rheumatic autoimmune diseases among adult patients with MS or NMO and their families, but there are no studies in the pediatric population.</p></div><div><h3>Objective</h3><p>To evaluate an association of MS and NMO with autoimmune rheumatic diseases in pediatric patients.</p></div><div><h3>Method</h3><p>22 patients younger than 21 years old with MS or NMO diagnosed before the age of 18 years were evaluated regarding epidemiological data, clinical presentation, association with autoimmune diseases, family history of autoimmune diseases, laboratory findings, imaging studies and presence of auto‐antibodies.</p></div><div><h3>Results</h3><p>Among the patients studied, there was a prevalence of females (68.1%). The mean age of symptoms onset was 8 years and 9 months and the mean current age was 16 years and 4 months. Two patients (9%) had a history of associated autoimmune rheumatic disease: one case of juvenile dermatomyositis in a patient with NMO and another of systemic lupus erythematosus in a patient with MS. Three patients (13%) had a family history of autoimmunity in first‐degree relatives. ANA was found positive in 80% of patients with NMO and 52% of patients with MS. About 15% of ANA‐positive patients were diagnosed with rheumatologic autoimmune disieses.</p></div><div><h3>Conclusion</h3><p>Among patients with demyelinating diseases diagnosed in childhood included in this study there was a high frequency of ANA positivity but a lower association with rheumatologic autoimmune diseases than that observed in studies conducted in adults.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46057689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacto do apoio social sobre os sintomas de mulheres brasileiras com fibromialgia","authors":"Rodrigo Pegado de Abreu Freitas ,&nbsp;Sandra Cristina de Andrade ,&nbsp;Maria Helena Constantino Spyrides ,&nbsp;Maria Thereza Albuquerque Barbosa Cabral Micussi ,&nbsp;Maria Bernardete Cordeiro de Sousa","doi":"10.1016/j.rbr.2016.05.002","DOIUrl":"10.1016/j.rbr.2016.05.002","url":null,"abstract":"<div><p>We aimed to assess the impact of social support on symptoms in Brazilian women with FM. An observational, descriptive study enrolling 66 women who met the 1990 American College of Rheumatology (ACR) criteria. Social support was measured by the Social Support Survey (MOS-SSS), functionality was evaluated using the Fibromyalgia Impact Questionnaire (FIQ), depression was assessed using the Beck Depression Inventory (BDI), anxiety was measured using the Hamilton Anxiety Scale (HAS), affectivity was measured by Positive and Negative Affect Schedule (PANAS), and algometry was carried out to record pressure pain threshold (PPth) and tolerance (PPTo) at 18 points recommended by the ACR. Patients were divided into normal (NSS) or poor social support (PSS) groups with PSS defined as having a MOS-SSS score below the 25th percentile of the entire sample. Mann–Whitney or Unpaired <em>t</em>-test were used to compare intergroup variables and Fisher's for categorical variables. Analysis of covariance and Pearson correlation test were used. No differences in sociodemographic variables between PSS and NSS were found. Differences between NSS and PSS groups were observed for all four subcategories of social support and MOS-SSS total score. Significant differences between NSS and PSS on depression (<em>p</em> <!-->=<!--> <!-->0.007), negative affect (<em>p</em> <!-->=<!--> <!-->0.025) and PPTh (<em>p</em> <!-->=<!--> <!-->0.016) were found. Affectionate subcategory showed positive correlation between pain and positive affect in PSS. Positive social interaction subcategory showed a negative correlation between FIQ and depression state. Therefore social support appears to contribute to ameliorate mental and physical health in FM.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.05.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41738488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expressão não equilibrada do receptor de hidrocarboneto arílico nos linfócitos T CCR6+ CD4+ e CD4+ CD25+ do sangue periférico na artrite reumatoide","authors":"Lin Cheng ,&nbsp;Long Qian ,&nbsp;Yue Tan ,&nbsp;Guo‐Sheng Wang ,&nbsp;Xiao‐Mei Li ,&nbsp;Xiang‐Pei Li ,&nbsp;Chao‐Yin Luo","doi":"10.1016/j.rbr.2016.04.003","DOIUrl":"10.1016/j.rbr.2016.04.003","url":null,"abstract":"<div><h3>Objective</h3><p>The goal of this study was to analyze the role of aryl hydrocarbon receptor in peripheral blood CCR6⁺CD4⁺ and CD4⁺CD25⁺T cells of patients with rheumatoid arthritis.</p></div><div><h3>Methods</h3><p>Flow cytometry was applied to determine the proportion of AhR positive cells in CCR6⁺CD4⁺T, CD4⁺CD25⁺T and peripheral blood peripheral mononuclear cells from each subject. AhR mRNA and CYP1A1 mRNA relative expression levels were tested by real-time PCR.</p></div><div><h3>Results</h3><p>The percentage of AhR positive cells in peripheral blood mononuclear cells was higher in RA group than that in healthy cases [(35.23<!--> <!-->±<!--> <!-->10.71)% <em>vs.</em> (18.83<!--> <!-->±<!--> <!-->7.32)%, <em>p</em> <!-->&lt;<!--> <!-->0.01]. The expression levels of AhR and CYP1A1 were both increased in patients with RA while compared to controls [(3.71<!--> <!-->±<!--> <!-->1.63) <em>vs.</em> (2.00<!--> <!-->±<!--> <!-->1.27), <em>p</em> <!-->=<!--> <!-->0.002; (2.62<!--> <!-->±<!--> <!-->2.08) <em>vs.</em> (0.62<!--> <!-->±<!--> <!-->0.29), <em>p</em> <!-->&lt;<!--> <!-->0.01, respectively]. In RA patients, the percentage of AhR positive cells in CD4⁺CD25⁺T cells was significantly lower than that from controls [17.90 (6.10<!--> <!-->±<!--> <!-->80.10)% <em>vs.</em> (52.49<!--> <!-->±<!--> <!-->19.18)%, <em>p</em> <!-->&lt;<!--> <!-->0.01]; In healthy controls, the percentage of AhR positive cells in CD4⁺CD25⁺T cells was significantly higher than that in CCR6⁺CD4⁺T cells, and was also significantly higher than that in PBMCs [(52.49<!--> <!-->±<!--> <!-->19.18)% <em>vs.</em> (23.18<!--> <!-->±<!--> <!-->5.62)% <em>vs.</em> (18.06<!--> <!-->±<!--> <!-->7.80)%, <em>X</em>² <!-->=<!--> <!-->24.03, <em>p</em> <!-->&lt;<!--> <!-->0.01]; in RA patients, the percentage of AhR positive cells in CCR6⁺CD4⁺T cells was significantly increased than that in CD4⁺CD25⁺T cells and PBMCs [(46.02<!--> <!-->±<!--> <!-->14.68)% <em>vs.</em> 17.90 (6.10<!--> <!-->±<!--> <!-->80.10)% <em>vs.</em> (34.22<!--> <!-->±<!--> <!-->10.33)%, <em>X</em>² <!-->=<!--> <!-->38.29, <em>p</em> <!-->&lt;<!--> <!-->0.01]; Nevertheless, no statistically significant relationship was found between clinical data and AhR positive cells in CCR6⁺CD4⁺T and CD4⁺CD25⁺T cells.</p></div><div><h3>Conclusion</h3><p>AhR may participate in the pathological progress of RA by controlling the differentiation of Th17 and Treg cells in peripheral blood.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.04.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55035850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tratamento da osteoporose pós‐menopáusica: um algoritmo baseado na literatura para uso no sistema público de saúde","authors":"Ellen Luz Pereira Caires ,&nbsp;Mailze Campos Bezerra ,&nbsp;Ana Flávia Torquato de Araújo Junqueira ,&nbsp;Sheila Márcia de Araújo Fontenele ,&nbsp;Silvana Cristina de Albuquerque Andrade ,&nbsp;Catarina Brasil d’Alva","doi":"10.1016/j.rbr.2016.12.001","DOIUrl":"10.1016/j.rbr.2016.12.001","url":null,"abstract":"<div><p>Bisphosphonates are considered first‐line agents in the treatment of postmenopausal osteoporosis based on extensive experience of use, safety, and proven efficacy in reducing vertebral, non‐vertebral and femur fractures. However, post‐marketing reports based on the treatment of millions of patients/year over lengthy periods of time have revealed the occurrence of initially unexpected adverse effects, such as osteonecrosis of the jaw and atypical femoral fracture, leading to the restriction of treatment duration with bisphosphonates by global regulatory agencies. However, despite the association between these effects and bisphosphonates, this risk should be analyzed in the context of osteoporosis treatment, alongside the benefit of preventing osteoporotic fractures and their clinical consequences. Therefore, we consider it plausible to discuss the restriction to the use of bisphosphonates, possible indications for prolonged treatment and alternative therapies following the suspension of this drug class for patients with persistent high risk of fracture after initial treatment, especially considering the problems of public health funding in Brazil and the shortage of drugs provided by the government. Thus, to standardize the treatment of osteoporosis in the public health care system, we aim to develop a proposal for a scientifically‐based pharmacological treatment for postmenopausal osteoporosis, establishing criteria for indication and allowing the rational use of each pharmacological agent. We discuss the duration of the initial bisphosphonate treatment, the therapeutic options for refractory patients and potential indications of other classes of drugs as first‐choice treatment in the sphere of public health, in which assessing risk and cost effectiveness is a priority.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.12.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41442773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"As mulheres com síndrome de Sjögren estão satisfeitas com sua atividade sexual?","authors":"Hatice Isik ,&nbsp;Metin Isik ,&nbsp;Oner Aynioglu ,&nbsp;Deniz Karcaaltincaba ,&nbsp;Ahmet Sahbaz ,&nbsp;Tugba Beyazcicek ,&nbsp;Mehmet Ibrahim Harma ,&nbsp;Nejat Demircan","doi":"10.1016/j.rbr.2016.05.009","DOIUrl":"10.1016/j.rbr.2016.05.009","url":null,"abstract":"<div><h3>Objective</h3><p>Females with Sjögren's Syndrome (SS) often experience vaginal dryness and dyspareunia, along with glandular and extraglandular symptoms. We aimed to evaluate sexual function and life quality in women with SS.</p></div><div><h3>Methods</h3><p>Forty-six premenopausal women with SS and 47 age-matched controls were studied. Age, duration of the disease, medications, and comorbid diseases were noted. Participants completed 36-Item Short Form Health Survey (SF-36) and Female Sexual Function Index (FSFI). Patients were asked about vaginal discharge and itching in the last month, and if they informed their rheumatologists about any sexual problems. Gynecologic examinations were performed and vaginal smears were taken on each participant.</p></div><div><h3>Results</h3><p>The median total scores of FSFI were significantly lower in the SS group than the controls [17.12 (2.4–27.8) and 27.4 (16.9–36.0), respectively, <em>p</em> <!-->&lt;<!--> <!-->0.001]. In the SS group, 37 (80.4%) and in the control group 18 (38.3%) of patients were sexually dissatisfied (<em>p</em> <!-->&lt;<!--> <!-->0.001). Vaginal dryness and lubricant use were significantly increased in patients with SS compared to controls (<em>p</em> <!-->&lt;<!--> <!-->0.001). Life quality scores were significantly lower in patients with SS than the controls (<em>p</em> <!-->&lt;<!--> <!-->0.001). Vaginal dryness was negatively correlated with FSFI total (<em>r</em> <!-->=<!--> <!-->−0.312, <em>p</em> <!-->=<!--> <!-->0.035) and subscores except desire and arousal. Physical functioning, role physical and role emotional scores were positively correlated with total FSFI scores (<em>r</em> <!-->=<!--> <!-->0.449, <em>p</em> <!-->=<!--> <!-->0.002, <em>r</em> <!-->=<!--> <!-->0.371, <em>p</em> <!-->=<!--> <!-->0.011, <em>r</em> <!-->=<!--> <!-->0.299, <em>p</em> <!-->=<!--> <!-->0.043, respectively).</p></div><div><h3>Conclusions</h3><p>Women with SS experience less satisfaction with sexual activity, which can be affected by age, vaginal dryness, physical pain, and impaired function due to the disease. Therefore, rheumatologists should pay attention to these symptoms and management.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.05.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48967792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possíveis ligações entre a osteoporose e a doença periodontal","authors":"Daniela Cia Penoni ,&nbsp;Anna Thereza Thomé Leão ,&nbsp;Tatiana Melo Fernandes ,&nbsp;Sandra Regina Torres","doi":"10.1016/j.rbr.2015.12.002","DOIUrl":"10.1016/j.rbr.2015.12.002","url":null,"abstract":"","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2015.12.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48032420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efeitos do uso do hormônio de crescimento em crianças e adolescentes com artrite idiopática juvenil: revisão sistemática","authors":"Renan Bazuco Frittoli ,&nbsp;Barbara Sugui Longhi ,&nbsp;Amanda Meireles Silva ,&nbsp;Antônio de Azevedo Barros Filho ,&nbsp;Maria Ângela Reis de Góes Monteiro ,&nbsp;Simone Appenzeller","doi":"10.1016/j.rbr.2016.04.004","DOIUrl":"10.1016/j.rbr.2016.04.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Children with Juvenile Idiopathic Arthritis (JIA) often have impaired growth and short stature. There is evidence that the therapeutic use of growth hormone (GH) is useful and safe in these patients.</p></div><div><h3>Objective</h3><p>To analyze the effects of GH use in patients with JIA.</p></div><div><h3>Method</h3><p>A systematic review of the literature over the last 18 years in Medline and Embase databases. The criteria were analyzed independently by the researchers. We used the following keywords: “growth hormone”, “arthritis, juvenile”, “arthritis, rheumatoid”, “child” and “adolescent”.</p></div><div><h3>Results</h3><p>Among the 192 identified articles, 20 corresponded to the inclusion criteria. Seventeen longitudinal studies and 3 case reports were found. Most studies analyzed observed increased growth, muscle mass and bone mass using GH. Adverse effects observed were glucose intolerance, diabetes, bone deformities, osteonecrosis, reactivation of the disease and low final height.</p></div><div><h3>Conclusion</h3><p>The majority of studies reported positive effects after the therapeutic use of GH, but some variability in response to treatment was observed. The combination of growth hormone with other drugs seems to be a good option.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.04.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47935754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tradução e validação do Neck Bournemouth Questionnaire para o português do Brasil","authors":"Danilo Harudy Kamonseki,&nbsp;Luísa Cedin,&nbsp;Jaqueline Tavares‐Preto,&nbsp;Beatriz de Oliveira Peixoto,&nbsp;Sandro Rostelato‐Ferreira","doi":"10.1016/j.rbr.2016.09.002","DOIUrl":"10.1016/j.rbr.2016.09.002","url":null,"abstract":"<div><h3>Objective</h3><p>To translate the Neck Bournemouth Questionnaire to Brazilian Portuguese, cross‐culturally adapt, and to verify its validity and its reliability.</p></div><div><h3>Methods</h3><p>The development of the Brazilian version of Neck Bournemouth Questionnaire (Brazil‐NBQ) was based on the guideline proposed by Guillemin. The applied process consisted of translation, back‐translation, committee review and pre‐test. Sixty‐one volunteers presenting neck pain participated in this study. Thirty‐five of them participated during pre‐testing phase to verify the instrument comprehension, and the remaining 26 took part during psychometric analysis. Psychometric evaluation included interrater and intrarater reliability and construct validity (correlation among Brazil‐NBQ, SF‐36, Numerical rating score and Neck Disability Index).</p></div><div><h3>Results</h3><p>Some terms and expressions were changed to obtain cultural equivalence for Brazil‐NBQ during the translation phase. The NBQ showed an intrarater ICC of 0.96 and interrater ICC of 0.87. Construct validity analysis showed moderate correlations with SF‐36 and strong correlation with Numerical rating score and Neck Disability Index.</p></div><div><h3>Conclusion</h3><p>Neck Bournemouth Questionnaire was translated and culturally adapted to Portuguese language, and it demonstrated to be valid and reliable to evaluate patientś neck pain.</p></div>","PeriodicalId":48991,"journal":{"name":"Revista Brasileira De Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbr.2016.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48311470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}